Pharmacokinetics of asundexian with combined CYP3A and P‐gp inhibitors and an inducer: Target in vitro and in vivo studies.

MLA

Kanefendt, Friederike, et al. “Pharmacokinetics of Asundexian with Combined CYP3A and P‐gp Inhibitors and an Inducer: Target in Vitro and in Vivo Studies.” British Journal of Clinical Pharmacology, vol. 90, no. 4, Apr. 2024, pp. 1036–49. EBSCOhost, https://doi.org/10.1111/bcp.15981.

APA

Kanefendt, F., Brase, C., Jungmann, N., Fricke, R., Engelen, A., & Schmitz, S. (2024). Pharmacokinetics of asundexian with combined CYP3A and P‐gp inhibitors and an inducer: Target in vitro and in vivo studies. British Journal of Clinical Pharmacology, 90(4), 1036–1049. https://doi.org/10.1111/bcp.15981

Chicago

Kanefendt, Friederike, Christine Brase, Natalia Jungmann, Robert Fricke, Anna Engelen, and Sebastian Schmitz. 2024. “Pharmacokinetics of Asundexian with Combined CYP3A and P‐gp Inhibitors and an Inducer: Target in Vitro and in Vivo Studies.” British Journal of Clinical Pharmacology 90 (4): 1036–49. doi:10.1111/bcp.15981.